STOCK TITAN

Fulgent Genetics Inc - FLGT STOCK NEWS

Welcome to our dedicated news page for Fulgent Genetics (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fulgent Genetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fulgent Genetics's position in the market.

Rhea-AI Summary
Fulgent Genetics, Inc. (FLGT) reports Full Year 2023 Total Revenue of $289.2 million, with Core Revenue growing 44% year-over-year to $262.1 million. The company ended 2023 with $847.7 million in cash, cash equivalents, and investments in marketable securities. Despite a GAAP loss of $167.8 million for the full year, Fulgent showcased progress in its core business and therapeutic development ventures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.14%
Tags
earnings
-
Rhea-AI Summary
Fulgent Genetics, Inc. (FLGT) announces the release of its Q4 and full year 2023 financial results on February 28, 2024. The company, known for its clinical diagnostic and therapeutic development businesses, will host a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
earnings
-
Rhea-AI Summary
COO announces testing services for CBR families to proactively seek additional information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
Rhea-AI Summary
COO announces testing services for CBR families to proactively seek additional information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
Rhea-AI Summary
Fulgent Genetics, Inc. (NASDAQ: FLGT) to Participate in Piper Sandler 35th Annual Healthcare Conference. The company's management team will conduct a presentation on November 28, 2023, with a live webcast available on the Investor Relations section of the Fulgent Genetics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences
-
Rhea-AI Summary
Fulgent Genetics announces data from two poster presentations at the Society for Immunotherapy of Cancer Annual Meeting. The first poster explores the role of liquid biopsy technology in comparing ctDNA variants in plasma and tissue. The second poster highlights progress for Fulgent Pharma's lead therapeutic candidate, FID-007, in various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Fulgent Genetics, Inc. (NASDAQ: FLGT) reported total revenue of $85 million for Q3 2023, with core revenue growing 17% YoY to $66 million. The company generated a GAAP loss of $13.1 million and a non-GAAP loss of $11.7 million. Adjusted EBITDA was $18.1 million, and cash flow from operations was $10.2 million. Fulgent maintains a strong financial profile with $851 million in cash, cash equivalents, and investments in marketable securities as of September 30, 2023. The company reiterates its full-year 2023 core revenue guidance of $260 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.24%
Tags
earnings
-
Rhea-AI Summary
Fulgent Genetics announces two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The presentations will focus on critical clinical evaluation of plasma to tumor tissue concordance by cancer type and a novel nano-drug delivery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
none
-
Rhea-AI Summary
Fulgent Genetics to release Q3 2023 financial results on November 3, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
earnings
Rhea-AI Summary
Fulgent Genetics, Inc. reports total revenue of $68 million and record core revenue of $67 million for the second quarter of 2023. The company raises its full-year 2023 core revenue guidance to $260 million. Fulgent Genetics also generated cash flow from operations of $9.7 million and has cash, cash equivalents, and investments in marketable securities of $846.8 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
earnings
Fulgent Genetics Inc

Nasdaq:FLGT

FLGT Rankings

FLGT Stock Data

646.03M
19.89M
31.77%
49.38%
1.67%
Dental Laboratories
Manufacturing
Link
US
Temple City

About FLGT

mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques